Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$30.5M Sell
23,109
-1,022
-4% -$1.4M 0.69% 21
2025
Q4
$25.8M Buy
24,131
+11,660
+93% +$12.2M 0.55% 27
2025
Q3
$12.1M Sell
12,471
-1,886
-13% -$1.48M 0.38% 50
2025
Q2
$11.5M Buy
14,357
+9,579
+200% +$6.87M 0.36% 51
2025
Q1
$3.17M Sell
4,778
-1,115
-19% -$811K 0.24% 93
2024
Q4
$4.08M Buy
5,893
+5,560
+1,670% +$3.99M 0.26% 75
2024
Q3
$277K Buy
333
+79
+31% +$70.6K 0.05% 148
2024
Q2
$260K Buy
254
+19
+8% +$18.3K 0.05% 132
2024
Q1
$228K Buy
+235
New +$208K 0.05% 87

Other funds holding ASML

Callan Family Office's ASML Position: Q1 2026 in Review

Callan Family Office reduced its ASML (ASML) stake by 4.2% in Q1 2026, selling an estimated $1.4M and leaving 23,109 shares worth $30.5M. The position accounts for 0.69% of the portfolio, ranked #21.

Callan Family Office first reported a position in ASML in Q1 2024 and has held it in 9 quarters since. 2,188 funds tracked by Wall St. Rank hold ASML as of Q1 2026.

  • Callan Family Office held 23,109 shares of ASML worth $30.5M as of Q1 2026.
  • Callan Family Office sold 1,022 ASML shares in Q1 2026, an estimated $1.4M.
  • ASML made up 0.69% of Callan Family Office's portfolio in Q1 2026, its #21 holding.
  • Callan Family Office first reported a position in ASML in Q1 2024 and has held it in 9 quarters since.
  • 2,188 funds tracked by Wall St. Rank held ASML as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.